|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:administeredBy
|
oral tablet
intravenous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
1991
|
|
gptkbp:ATCCode
|
L01BB05
|
|
gptkbp:brand
|
gptkb:Fludara
|
|
gptkbp:CASNumber
|
75607-67-9
|
|
gptkbp:chemicalFormula
|
C10H13FN5O7P
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to fludarabine
|
|
gptkbp:developedBy
|
gptkb:Germany
|
|
gptkbp:discoveredBy
|
Berlex Laboratories
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fludarabine phosphate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
purine analog
inhibits DNA synthesis
|
|
gptkbp:metabolism
|
2-fluoro-ara-adenine
|
|
gptkbp:molecularWeight
|
365.22 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
fatigue
myelosuppression
increased infection risk
|
|
gptkbp:synonym
|
gptkb:2-fluoro-ara-AMP
fludarabine monophosphate
|
|
gptkbp:usedFor
|
leukemia
chronic lymphocytic leukemia
acute myeloid leukemia (off-label)
|
|
gptkbp:bfsParent
|
gptkb:fludarabine
|
|
gptkbp:bfsLayer
|
7
|